A Long-Term Study of E0302

First Published on Clinicaltrials.gov: 3/6/2007
Status: Currently Recruiting
ClinicalTrials.gov ID: NCT00445172
Sponsor: Eisai Limited
Purpose: The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).
Phase: II/III
Treatment Type: Injection
Trial Type: Open label
Estimated Enrollment: 300
Eligibility: 20 years and older. Both Genders. No healthy volunteers
Details: One arm study: experimental intramuscular injection E0302 twice a week.
Collaborator(s):
Location(s):
  • Japan
Primary Investigator: Kazunori Saeki, Clinical Development. Neuroscience PCU. Eisai Co.,Ltd.
Contact:
Trial Protocol as Published on Clinicaltrials.gov:
ClinicalTrials.gov   Download PDF
ALS Forum: